NCT00843037 2024-10-17
SNIPP
University Health Network, Toronto
Phase 2 Completed
Clinical Trials
11 trialsNCT03641326 2022-04-19
Sunitinib in Sarcomas of the Central Nervous System
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT00499473 2016-02-29
Sunitinib in Treating Patients With Recurrent Malignant Gliomas
National Cancer Institute (NCI)
Phase 2 Completed
NCT00589784 2016-01-25
Phase II Trial of Sunitinib (SU011248) in Patients With Recurrent or Inoperable Meningioma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00462982 2015-12-30
Sunitinib in Treating Patients With Brain Metastases Caused by Kidney Cancer or Melanoma
Memorial Sloan Kettering Cancer Center
Phase 2 Completed
NCT00923117 2015-09-30
Sunitinib to Treat Recurrent Brain Cancer
National Institutes of Health Clinical Center (CC)
Phase 2 Terminated
NCT01462695 2015-08-27
Sunitinib Malate in Treating Younger Patients With Recurrent, Refractory, or Progressive Malignant Glioma or Ependymoma
National Cancer Institute (NCI)
Phase 2 Completed
NCT00910039 2014-09-29
Sunitinib Malate After Stereotactic Radiosurgery in Treating Patients With Newly Diagnosed Brain Metastases
Case Comprehensive Cancer Center
Phase 2 Terminated
NCT00570908 2014-09-18
Brain Mets - Capecitabine Plus Sunitinib and WBRT
Baylor Breast Care Center
Phase 2 Terminated
NCT00606008 2012-11-19
A Phase II Trial of Sutent (Sunitinib; SU011248) for Recurrent Anaplastic Astrocytoma and Glioblastoma
H. Lee Moffitt Cancer Center and Research Institute
Phase 2 Completed
NCT00372775 2011-02-24
Study Tests The Safety And Effectiveness Of SU011248 In Patients With Non-Small Cell Lung Cancer Having Brain Metastases
Pfizer
Phase 2 Completed